|
|
|
|
ActiqPharmaLive.com (press release), The company currently markets four proprietary products in the United States: PROVIGIL, GABITRIL(R) (tiagabine hydrochloride), ACTIQ(R) (oral transmucosal ... Cephalon CEO readies for 4 new drug launches Dec 19, 2005 Reuters He anticipates a late 2006 launch of OVF for extreme cancer pain that he believes will more than make up for revenue lost when its pain drug Actiq goes off ... FDA Issues Approvable Letter for VIVITROL(TM) (Formerly VIVITREX(R ... Dec 28, 2005 Finanzen.net, ...company currently markets four proprietary products in theUnited States: PROVIGIL(R) (modafinil) (C-IV), GABITRIL(R) (tiagabinehydrochloride), ACTIQ(R) (oral ... Cephalon, Inc. Completes Acquisition of Zeneus Holdings Limited Dec 22, 2005 Yahoo! News (press release) ...markets four proprietary products in the United States: PROVIGIL® (modafinil) [C-IV], GABITRIL® (tiagabine hydrochloride), ACTIQ® (oral transmucosal ... Cephalon, Inc. Completes Acquisition of Zeneus Holdings Limited Dec 22, 2005 Boursorama, ...company currently markets four proprietary products in the United States: PROVIGIL(R) (modafinil) [C-IV], GABITRIL(R) (tiagabine hydrochloride), ACTIQ(R) (oral ... |
|
Home Copyright phasechange.org 2006. All Rights Reserved. |